ZEO Scientifix Inc. reported full year (FY) revenues of USD 5.2 million for the fiscal year ended October 31, 2025, representing a 12.5% increase. The company’s Higher Concentration Allogenic Aesthetic Biologics segment recorded revenues of USD 2.2 million, while the Lower Concentration Allogenic Aesthetic Biologics segment generated USD 1.4 million. ZEO Scientifix Inc. remains dependent on additional investment capital to fund ongoing operating expenses and research and development costs. The company stated that it does not expect recently issued accounting pronouncements to have a material effect on its financial condition or results of operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ZEO Scientifix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-000763), on January 29, 2026, and is solely responsible for the information contained therein.